Copy number variants (CNVs) are major contributors to genetic disorders 1 . We have dissected a region of the 16p11.2 chromosomewhich encompasses 29 genes-that confers susceptibility to neurocognitive defects when deleted or duplicated 2,3 . Overexpression of each human transcript in zebrafish embryos identified KCTD13 as the sole message capable of inducing the microcephaly phenotype associated with the 16p11.2 duplication 2-5 , whereas suppression of the same locus yielded the macrocephalic phenotype associated with the 16p11.2 deletion 5,6 , capturing the mirror phenotypes of humans. Analyses of zebrafish and mouse embryos suggest that microcephaly is caused by decreased proliferation of neuronal progenitors with concomitant increase in apoptosis in the developing brain, whereas macrocephaly arises by increased proliferation and no changes in apoptosis. A role for KCTD13 dosage changes is consistent with autism in both a recently reported family with a reduced 16p11.2 deletion and a subject reported here with a complex 16p11.2 rearrangement involving de novo structural alteration of KCTD13. Our data suggest that KCTD13 is a major driver for the neurodevelopmental phenotypes associated with the 16p11.2 CNV, reinforce the idea that one or a small number of transcripts within a CNV can underpin clinical phenotypes, and offer an efficient route to identifying dosage-sensitive loci.
Copy number variants (CNVs) are major contributors to genetic disorders 1 . We have dissected a region of the 16p11.2 chromosomewhich encompasses 29 genes-that confers susceptibility to neurocognitive defects when deleted or duplicated 2, 3 . Overexpression of each human transcript in zebrafish embryos identified KCTD13 as the sole message capable of inducing the microcephaly phenotype associated with the 16p11.2 duplication 2-5 , whereas suppression of the same locus yielded the macrocephalic phenotype associated with the 16p11.2 deletion 5, 6 , capturing the mirror phenotypes of humans. Analyses of zebrafish and mouse embryos suggest that microcephaly is caused by decreased proliferation of neuronal progenitors with concomitant increase in apoptosis in the developing brain, whereas macrocephaly arises by increased proliferation and no changes in apoptosis. A role for KCTD13 dosage changes is consistent with autism in both a recently reported family with a reduced 16p11.2 deletion and a subject reported here with a complex 16p11.2 rearrangement involving de novo structural alteration of KCTD13. Our data suggest that KCTD13 is a major driver for the neurodevelopmental phenotypes associated with the 16p11.2 CNV, reinforce the idea that one or a small number of transcripts within a CNV can underpin clinical phenotypes, and offer an efficient route to identifying dosage-sensitive loci.
Copy number changes have emerged as a notable source of genetic variation contributing to the human genetic disease risk 1 . In addition to genomic disorders such as Charcot-Marie-Tooth disease, DiGeorge syndrome and others 7, 8 , in which large deletions and duplications represent penetrant alleles for discrete syndromic phenotypes, recent advances have highlighted the contribution of such genomic events in a broad range of both common and rare traits (see the DECIPHER consortium website, http://decipher.sanger.co.uk). Systematic surveys of neurodevelopmental disorders have uncovered a particularly high incidence of both inherited and de novo CNVs that can confer either causality or susceptibility [9] [10] [11] [12] . For example, deletions in 1q21.1 and 15q13.3 have been associated with schizophrenia, whereas duplications in 15q11-15q13 and 7q22-7q31 have been associated with autism spectrum disorder (ASD; see review 1 ).
A 600-kb deletion on 16p11.2, encompassing 29 annotated genes, has been significantly and reproducibly associated with a range of neurocognitive defects, including epilepsy, autism and ASD 2 , whereas the reciprocal duplication has been associated with autism and schizophrenia 3 . In addition, extended phenotypic analyses of patients with such genomic lesions have revealed strong mirroring comorbidities: the common 16p11.2 deletion is associated with paediatric neurodevelopmental disorders, including autism, diabetes-independent obesity 5 and macrocephaly 6 , whereas the reciprocal duplication is associated with both autism and schizophrenia, as well as anorexia and microcephaly [2] [3] [4] [5] 13 . Moreover, a recent post hoc analysis of ASD and schizophrenia loci has revealed that such comorbidities might be causally linked to each other, with macrocephaly shown to be associated with ASD, and microcephaly with schizophrenia 31 .
A pervasive challenge in the interpretation of CNV discovery is the transition from the detection of a genomic lesion that can often span large regions encompassing many genes to the identification of the critical loci whose dosage sensitivity drives the phenotype. For some disorders, this has been achieved through the discovery of highly penetrant point mutations at a single locus; for example, mutations in PMP22 are sufficient to cause CMT 14 , whereas mutations in RAI1 cause Smith-Magenis syndrome 15 . In other disorders, gene-specific genomic alterations such as chromosomal translocations, inversions or small coding deletions can narrow the critical region to a single gene (for example, MBD5 in 2q23.1 microdeletion syndrome 16 ). Alternatively, systematic functional dissection through mouse mutagenesis has yielded strong candidates; ablation of Tbx1 recapitulates the cardiac phenotypes of VCSF 17 ; similarly, knockout of Shank3 captures most of the phenotypes seen in the terminal 22q deletion that causes Phelan-McDermid syndrome 18 . However, these approaches are considerably more challenging for common phenotypes and genetically heterogeneous disorders: systematic engineering of the mouse genome for each gene in a CNV can be impractical, and rare mutations involved in complex traits are likely to exhibit both reduced penetrance and variable expressivity.
Manipulation of zebrafish embryos is an attractive alternative method to discover human dosage-sensitive genes, particularly when the CNV under investigation has mirrored anatomical phenotypes that are detectable during early development and that can therefore be assayed using a combination of gene suppression and overexpression experiments 19 . Given the association between the 16p11.2 CNV and changes in head size, we proposed that (1), systematic overexpression of each of the 29 genes in the common duplication might yield a defined, reproducible set of transcripts, some of which might cause microcephaly; and (2) reciprocal suppression of these genes should yield the macrocephalic phenotype seen in the 16p11.2 deletion. To test these possibilities, we first queried the zebrafish genome by reciprocal BLAST (basic local alignment search tool) for each of the 29 target genes ( Fig. 1a ) and identified 24 orthologues ( Supplementary Table 1) , with five genes, SPN, QPRT, C16orf54, TMEM219 and C16orf92 found only in placental mammals. In a manner akin to the classic Drosophila misexpression experiments, we generated capped messenger RNA for all 29 human genes and injected zebrafish embryos at the two-cell stage with equimolar pairwise 'cocktail' combinations at two dosages of 25 pg and 50 pg. These commonly used ranges 20 were selected because they represent .0.25-0.5% of total polyA 1 mRNA in a zebrafish embryo 21 and are therefore likely to achieve substantial overexpression above the baseline of any single transcript.
One gene, TAOK2, required a reduction in mRNA dosage to 10 pg because of toxicity. For the remaining 28 genes, we observed no lethality or gross morphological defects at either 25 pg or 50 pg: random PCR with reverse transcription (RT-PCR) testing of nine injection cocktails, including KCTD13, showed persistence of the corresponding human mRNAs up to approximately 4.25 days post fertilization (d.p.f.) ( Supplementary Fig. 1e ). We therefore developed a surrogate measurement for head size at 4.25-4.5 d.p.f. using objective measurements, with the distance across the convex tips of the eye cups recorded in 50 embryos per injection, scored by an investigator who was uninformed of the composition of the injection cocktail ( Fig. 1b) . Only a single overexpression cocktail containing KCTD13 and CDIPT gave significant changes in head size (two-tailed t-test, P , 0.000001). Subsequent single-mRNA injections for the two genes indicated that the phenotype was driven exclusively by the overexpression of KCTD13; injection of KCTD13 at progressively increasing mRNA amounts yielded an increasing percentage of microcephalic embryos ( Fig. 2a, b and Supplementary Fig. 1a ). In contrast, the head size of embryos injected with CDIPT was indistinguishable from those injected with sham control (data not shown).
To validate the specificity of this phenotype and to investigate whether it was possible to also simulate the macrocephalic phenotype seen usually in 16p11.2del patients 4,13 , we designed a splice-blocking morpholino against the donor site of exon 3 of the sole kctd13 zebrafish orthologue. Injection of 10 ng of morpholino followed by RT-PCR testing showed ,70% reduction of kctd13 message at 4.5 d.p.f. ( Supplementary Fig. 1c ). Notably, this injection also yielded a significant increase in mean head size (P , 0.00001; Fig. 2a , b and Supplementary Fig. 1b ). This phenotype is specific to kctd13; a scrambled morpholino induced no phenotypes, whereas injection of 10 ng of morpholino and 50 pg of KCTD13 mRNA rescued both the microcephalic and macrocephalic phenotypes ( Supplementary Fig. 1d ). Importantly, measurement of the somitic trunk length of scored embryos showed no differences in length (or morphology; Supplementary Fig. 2 ), indicating that the head size differences are unlikely to be driven by gross developmental delay. There were also no defects in other structures, including the heart and the swim bladder.
To investigate the mechanism of the head size defects, we examined the developing brain of both macro-and microcephalic embryos. In situ hybridization with an antisense kctd13 probe showed that this transcript is expressed strongly in the developing brain. At 24 hours post fertilization (h.p.f.), kctd13 is strongly expressed in the anterior forebrain ( Supplementary Fig. 3a, f) , the midbrain and the hindbrain.
In later stages, kctd13 is expressed predominantly in the telencephalon, the diencephalon and the retina ( Supplementary Fig. 3b-e ). Staining both phenotype classes with terminal deoxynucleotidyl TdT-mediated dUTP nick end labelling (TUNEL) showed a significant increase in apoptosis exclusively in the microcephalic embryos. At the same time, phospho-histone H3 antibody staining revealed an increase in proliferating cells in the brain of kctd13 morphants and a reciprocal decrease of proliferating cells in overexpressant embryos ( Fig. 2 c, d ). Detailed analysis of transverse sections from embryos injected with either morpholino or KCTD13 mRNA confirmed that the observed phenotypes are probably driven by changes in the number of cells in the developing brain; the architecture and cell content of the Meckel's and palatoquadrate pharyngeal cartilages were normal, as was the overall cell content and architecture of the retina ( Fig. 3a-f ). Cell nuclei were counted at 4.5 d.p.f. (at the stage when the anatomical measurements were made) and this showed that there were significant reciprocal changes in the total number of cells in each of the telencephalon, diencephalon and mesencephalon ( Fig. 3k ). Furthermore, counting of HuC/D-positive cells (a marker for post-mitotic neurons; cells were positive for HuC and HuD (also known as ELAVL3 and ELAVL4)) in the telencephalon recapitulated the differences seen in total cell count but showed no difference in cell circumference ( Fig. 3l and Supplementary Fig. 4) , indicating that the changes in overall cell numbers and ultimate changes in head size are largely driven by changes in the numbers of mature neurons. These data, collected at 4.5 d.p.f., predict that the onset of the neuroanatomical defects would precede the manifestation of anatomical micro-or macrocephalic phenotypes. To test this possibility, we stained all three classes of embryos with HuC/D and acetylated tubulin at 2 d.p.f., by which time the head size of kctd13 morpholinos and overexpressants is indistinguishable from uninjected controls. We observed stark differences in the density and distribution of neurons, particularly in the forebrain, with concomitant loss of organization and bilateral symmetry (Fig. 3m ), as well as aberrant distribution of axonal tracks (Fig. 3n ).
Although the zebrafish brain bears many similarities with the mammalian brain in terms of developmental programming, we examined whether our findings might be relevant to cortical development in a mammalian system. Data mining of the Gene Expression Nervous System Atlas (GENSAT; http://www.gensat.org) and the Allen brain atlas (http://www.brain-map.org) revealed that human and mouse KCTD13 is expressed throughout development in neurons residing in the cortex, striatum, olfactory tubercle and hippocampus. We BOLA2  GIYD2  SULT1A4  SULT1A3   SPN  QPRT  C16orf54   MAZ  PRRT2  C16orf53   MVP  CDIPT  SEZ6L2  ASPHD1  KCTD13  TMEM219  TAOK2  HIRIP3  INO80E  DOC2A  C16orf92  FAM57B  ALDOA  PPP4C  TBX6  YPEL3  GDPD3  MAPK3 
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therefore designed short hairpin RNAs (shRNAs) against murine Kctd13 and tested their efficiency in a cultured mouse neuroblastoma cell line (Neuro-2a). One shRNA, which, similar to the kctd13 morpholino, downregulated the expression of endogenous message by ,70% ( Supplementary Fig. 5 ), was then co-transfected with a green fluorescent protein (GFP)-expressing plasmid into Neuro-2a cells. Two days after transfection, cells were pulsed with 5-bromodeoxyuridine (BrdU) and analysed for the effects of Kctd13 knockdown on cellular proliferation. Similar to the proliferation data from zebrafish morphants, depletion of Kctd13 resulted in a 34% increase (P , 0.01) in BrdU/ GFP-labelled cells (Fig. 4a ). Next, we injected the Kctd13 shRNA and GFP-expressing plasmid into the ventricular space of wild-type C57BL/6 embryos at embryonic day 13.5 (E13.5) and injected BrdU into pregnant dams 2 h before collection of electroporated embryos at E15.5. Knockdown of Kctd13 resulted in a twofold increase in BrdU/ GFP labelling within the ventricular zone (P , 0.001; Fig. 4b ), suggesting that Kctd13 is required to maintain the proliferative status of cortical progenitors in vivo. 
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The combination of our zebrafish and mouse data suggests that KCTD13 is a major driver of the head size phenotypes associated with the 16p11.2 CNV through the regulation of early neurogenesis. Our data do not exclude the possibility that other loci also have an independent contribution to the 16p11.2 deletion or duplication (16p11.2del/dup) anatomical phenotypes, and cannot directly answer the question of whether all of the observed pathology in 16p11.2del/ dup patients is driven by dosage changes in KCTD13. However, we were able to ask whether dosage changes of other loci inside the CNV might also be relevant to the head size phenotypes established by KCTD13. Specifically, we performed pairwise overexpressions of KCTD13 with each of the other 28 transcripts in the region and asked whether we could observe changes in the penetrance (percentile of microcephalic zebrafish in a clutch) or the expressivity (percentile changes in mean head size) of the KCTD13-established phenotype. We observed no changes in penetrance. However, pairwise expression with two other transcripts, MAPK3 and MVP increased significantly the expressivity of the phenotype from 18% for KCTD13 alone to 24% and 22%, respectively ( Supplementary Fig. 6 and Supplementary  Table 2 ), predicting that 16p11.2del/dup patients might have a more severe phenotype than individuals with heterozygous loss of function at KCTD13 alone.
Finally, we examined whether loss of KCDT13 in humans might be sufficient to cause some of the commonly observed phenotypes associated with the 16p11.2 deletion. During our analyses, a submicroscopic ,118-kb deletion in 16p11.2 that segregated with ASD and other neurodevelopmental abnormalities was discovered in a single three-generation pedigree 22 . This deletion encompasses five genes, MVP, CDIPT1, SEZ6L2, ASPHD1 and KCTD13, which is consistent with our hypothesis that haploinsufficiency at KCTD13 might contribute to 16p11.2 phenotypes. We performed a multiplex ligation-dependent probe amplification (MLPA; Supplementary Table 3 ) assay of this restricted region in 518 subjects that met diagnostic criteria (Autism Diagnostic Observational Schedule, ADOS 10 ) for autism or ASD. We found full-segment deletions in eight independent ASD subjects (1.54%; six deletions and two duplications), compared to just five such events from 8,328 controls (0.06%) 23 . We also noted the deletion of a single probe spanning exon 4 of KCTD13 in one proband with a narrow diagnosis of autism ( Supplementary Fig. 7 and Supplementary Table 3 ). The MLPA assay was replicated in the proband and the deletion was confirmed further by quantitative polymerase chain reaction (qPCR) on two independently obtained DNA samples (Supplementary Fig. 7) . Identical MLPA analyses, as well as confirmation of paternity by genotyping, were performed in both biological parents, revealing that the deletion arose de novo, and was restricted to the KCTD13 coding region, maximally spanning 9 kb and including exons 3, 4 and 5 ( Supplementary Fig. 7) . However, through seeking to precisely localize the breakpoints by custom tiled array comparative genomic hybridization (array CGH) of the entire 16p11.2 region, we found the rearrangement to be more complicated than expected. We discovered an additional, atypical ,300-kb deletion, distal to the classic 16p11.2 region, that was inherited from an asymptomatic mother. The deletion was confirmed by an independent Agilent 24 M feature array CGH, but the precise breakpoints could not be definitely localized as the rearrangement is mediated by a highly complex genomic region of segmental duplication 24 . The apparent complexity of these co-occurring events, including both inherited and de novo rearrangements, impacts multiple loci in addition to KCTD13, suggesting that this phenotype cannot be attributed solely to the KCTD13 alteration.
In summary, our data support a major contributory role for KCDT13 in the 16p11.2 CNV through four lines of evidence: first, the in vivo overexpression screen yielded microcephaly in 1 out of 29 genes; second, the reciprocal suppression of this locus mirrored the corresponding human 16p11.2del phenotypes; third, functional analyses established a neurogenic defect that was consistent across species; and fourth, KCTD13 lies in the putative ,118-kb critical region delineated in one family with ASD independent from our study, and here we found a complex rearrangement that includes a de novo alteration affecting a portion of the coding region in a patient with a narrow diagnosis of autism.
Given that the design of our screen relies on a heterologous system of expression, we do not exclude the possibility that other genes in the 16p11.2 CNV might also be relevant to human pathology but did not trigger phenotypes in zebrafish embryos, particularly the five transcripts not present in the zebrafish genome. Moreover, we do not know whether dosage imbalance of KCTD13 might regulate other phenotypes commonly associated with the 16p11.2 CNV, such as obesity and epilepsy [4] [5] [6] . However, it is reasonable to speculate that the neurodevelopmental changes seen after KCTD13 perturbation could contribute to those phenotypes. We note that loss-of-function mutations of another member of this family, KCTD7, cause progressive myoclonic epilepsy 25 , and that variants in KCTD15 have been associated with obesity 26 .
KCTD13 encodes the polymerase delta-interacting protein 1 (PDIP1), which interacts with the proliferating cell nuclear antigen 27 and therefore might have a role in the regulation of cell cycle during neurogenesis. Our studies might also shed light on disease architecture and on whether changes in neuronal populations can account for brain overgrowth phenotypes 28 . Although our data suggest that disregulated KCTD13 levels are sufficient to establish neuroanatomical defects, its genetic interaction with at least one more locus leads us to speculate that the point mutation event that would phenocopy the 16p11.2del might not be represented by single loss-of-function alleles at KCTD13, but at cis or trans alleles in KCTD13, MAPK3 or MVP, or combined haploinsufficiency of all three. Testing this possibility with sufficient statistical power will require the analysis of large cohorts.
The 16p11.2 CNV has been modelled in mice by chromosomal engineering, and neuroanatomical volumetric changes have been found in regions analogous to those evaluated in our study (for example, in the forebrain and midbrain) 29 . Our approach is likely to 
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be particularly useful in resolving a rapidly growing number of genomic regions implicated in a range of human genomic disorder phenotypes 30 that are involved in both deletion and duplication syndromes (such as 7q11.23 CNV) 10 and that have mirroring anatomical phenotypes that can be assayed in a physiologically relevant developmental system (such as 1q21.1, and 3q39 CNVs 1 ). Such analyses will expedite the identification of major dosage-sensitive loci and accelerate our biological understanding of CNVs that, together, account for a substantial fraction of the mutational burden of neurodevelopmental disorders 1, 11 .
METHODS SUMMARY
Morpholino, in vivo analysis of gene expression and embryo manipulations. The splice-blocking morpholino against Kctd13 was designed and obtained from Gene Tools, LLC (59-TCTAAGGGTACACGCCTGACCTGTA-39). Control morpholino was the scrambled nucleotide sequence from Gene Tools, LLC (59-CCTCTTACCTCAGTTACAATTTATA-39). Morpholino injection, RNA rescue and overexpression experiments were performed using a standard protocol (Supplementary Methods). Immunostaining and TUNEL assay. Embryos were fixed in 4% paraformaldehyde (PFA) or in Dent's fixative (80% methanol, 20% dimethylsulphoxide (DMSO)) overnight at 4 uC. Embryos were incubated in the first antibody solution, 1:750 anti-histone H3 (ser10)-R (sc-8656-R, Santa Cruz), 1:1000 anti-HuC/D (A21271, Invitrogen) and 1:1000 anti-acetylated tubulin (T7451, Sigma-Aldrich). Apoptotic cell death in zebrafish whole-mounts was detected according to a modification of the ApopTag rhodamine In Situ Apoptosis Detection kit (Chemicon) protocol. Embryos for cryosectioning were fixed, incubated in PBS containing sucrose 30%, embedded in Tissue-Tek O.C.T. Embedding Compound (Sakura Finetek) and sectioned at 7 mm. In utero electroporation. E13.5 embryos were injected with either control or Kctd13 shRNA constructs and a GFP-expressing vector. Forty-eight hours after electroporation, BrdU (100 mg kg 21 ) was injected intraperitoneally into the pregnant dams and embryos were harvested 2 h later. Embryo brains were processed and sectioned (20 mm) before staining with a BrdU antibody (Accurate). Short arm of chromosome 16 custom array CGH. DNA samples from the proband and both parents were labelled with Cy3 and co-hybridized with Cy5-labelled control DNA from an unaffected CEPH (Centre d'Étude du Polymorphisme Humain) individual obtained from Coriell (GM10851) to custom-made Nimblegen arrays. DNA labelling, hybridization and washing were performed according to Nimblegen protocols. Scanning was performed using a Roche/ Nimblegen MS200 Scanner. Image processing, quality control and data extraction were performed using the Nimblescan software v.2.6.
